FDA-approved1,2Evidence: Limited human dataCancer

Gallium Ga 68 dotatate1

Also called NETSPOT, Ga-68 DOTATATE1,2

Key takeaway

Gallium Ga 68 dotatate is a radioactive imaging agent: dotatate, a cyclic eight-amino-acid peptide that binds somatostatin receptors, carrying the positron-emitting isotope gallium-68.1 FDA approved the NETSPOT kit, which is used to prepare it, in 2016 for PET scans to locate somatostatin receptor-positive neuroendocrine tumors in adults and children.1,2 Approval rests on three open-label imaging studies. The label has no boxed warning and notes that it adds to a person’s long-term radiation exposure.1

Gallium Ga 68 dotatate at a glance

What it isDotatate (DOTA-Tyr3-octreotate), a cyclic eight-amino-acid peptide with a bound chelator, labelled with gallium-68 for PET imaging, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists NETSPOT, NDA 208547, with an original approval date of June 1, 2016. The label has no boxed warning.1,2
Human evidenceThree open-label, single-centre imaging studies in 97, 104 and 63 people with known or suspected neuroendocrine tumors, described in the label.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is gallium Ga 68 dotatate?

Dotatate, also known as DOTA-Tyr3-octreotate, is a cyclic peptide of eight amino acids joined to a chelator, DOTA, that holds a radioactive metal. Labelled with gallium-68, it becomes gallium Ga 68 dotatate, according to the label.1

In the United States it is prepared from the NETSPOT kit, approved under NDA 208547, according to Drugs@FDA.2

How does gallium Ga 68 dotatate work?

It binds to somatostatin receptors, most strongly to subtype 2, which many neuroendocrine tumor cells carry in large numbers. Gallium-68 emits positrons, so a PET scanner can show where it has collected, according to the label.1

What do human studies show?

In one study of 97 adults with known or suspected neuroendocrine tumors, scans were read by two blinded readers; among 50 patients with tumors found on CT or MRI, the gallium Ga 68 dotatate scan was positive in 48.1

In a second study of 104 patients, scans correctly found a tumor site in 29 of 36 patients with confirmed tumors and were falsely positive in 7 of 68 without. A third study, of 63 patients checked for recurrence, gave similar results, according to the label.1

What the evidence base contains

  • Small, short, or incompletely reported human study Three open-label, single-centre studies of PET imaging in people with known or suspected neuroendocrine tumors, in which scans agreed with other imaging or with a reference standard in most patients, described in the label.1

Evidence-strength label: Limited human data. How this label is assigned

Is gallium Ga 68 dotatate FDA-approved?

Yes. Drugs@FDA lists NETSPOT, NDA 208547, with an original approval date of June 1, 2016.2

The NETSPOT label cited here (DailyMed SPL version 23, published July 7, 2026) states that, after radiolabeling with gallium-68, it is indicated for use with PET to locate somatostatin receptor-positive neuroendocrine tumors in adults and children.1

The label has no boxed warning. It warns that it adds to a patient’s long-term cumulative radiation exposure, and describes hypersensitivity reactions, mostly rash and itching.1

Timeline

  1. FDA approves NETSPOT, NDA 208547, according to Drugs@FDA.2
  2. DailyMed publishes version 23 of the NETSPOT label, the version cited here.1

What is still unknown?

How often it misses tumors or flags tumors that are not there in wider use: in the label’s second study, scans missed a confirmed tumor in 7 of 36 patients.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Gallium Ga 68 dotatate: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Gallium Ga 68 dotatate are a bounded selection, not every registration or paper about Gallium Ga 68 dotatate. For the years before Gallium Ga 68 dotatate was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Gallium Ga 68 dotatate as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Gallium Ga 68 dotatate in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as NETSPOT for PET imaging of neuroendocrine tumors. Approval rests on three open-label imaging studies in 97, 104 and 63 people. The label has no boxed warning and notes added radiation exposure.↗↗

Status sources checked through November 16, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Gallium Ga 68 dotatate?

FDA-approved as NETSPOT for PET imaging of neuroendocrine tumors. Approval rests on three open-label imaging studies in 97, 104 and 63 people. The label has no boxed warning and notes added radiation exposure.↗↗

The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
6
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Gallium Ga 68 dotatate?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

13Selected dated records
15Connected citations
6Populated source years2016–2026
3/4Record lanes present

Registered human studies

Trial composition

5 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.

PhasesPhase 2 3Phase 1 2Early Phase 1 1
Status at observationCompleted 3Recruiting 2Active, not recruiting 1

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

6 of 6 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 6Case Reports 2Comparative Study 1Review 1Validation Study 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
13

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 13 dated records

Research hub

Explore the Gallium Ga 68 dotatate evidence record

Open all 13 records →
13Dated records
3Evidence types
13Cited public sources
6Source years

Change ledger

Recently changed for Gallium Ga 68 dotatate

Open all 13 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT03206060

PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
October 26, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03448458

PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
July 17, 2025
Evidence lane
Clinical trials

Official-source collections

Source records for Gallium Ga 68 dotatate

Open the full research atlas →
PubMed6

6 with attributed title, venue, publication-date, and type metadata.

  1. Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation.World journal of nuclear medicine · 2026 05 05
  2. Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT.The international journal of cardiovascular imaging · 2024 07 05
  3. Time-of-Flight PET/CT Imaging of Ga-68-Dotatate: Normal Pattern, SUV Quantification, and Differences from Non-Time-of-Flight Imaging.World journal of nuclear medicine · 2024 05 07
Explore all selected literature →
ClinicalTrials.gov6

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT03206060Registry update October 26, 2026 · current at observation
  2. NCT07150806Registry update August 13, 2026 · current at observation
  3. NCT04040088Registry update March 31, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Coverage by source year

Selected records span June 1, 2016 to October 26, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2
Dated updates connected to this profile · 13

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT03206060↗

    PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗

  2. Literature metadata

    Pulmonary Metastasis of Grade 1 Meningioma Mimicking a Carcinoid Tumor: A Case Report with FDG PET/CT, Ga-68 DOTATATE PET/CT, and Pathological Confirmation.↗

    PubMed lists PMID 42787917 in World journal of nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2026-05-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT07150806↗

    PeptideScanner retained ClinicalTrials.gov record NCT07150806 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04040088↗

    PeptideScanner retained ClinicalTrials.gov record NCT04040088 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT04069299↗

    PeptideScanner retained ClinicalTrials.gov record NCT04069299 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-03-31, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT03448458↗

    PeptideScanner retained ClinicalTrials.gov record NCT03448458 at 2026-11-16T17:36:42.191Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗

  7. Literature metadata

    Incidental Papillary Thyroid Carcinoma Detected by Ga-68 DOTATATE PET/CT: A Rare Case Study and Clinical Considerations.↗

    PubMed lists PMID 38262470 in Nuklearmedizin. Nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2024-01-23 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT.↗

    PubMed lists PMID 38967895 in The international journal of cardiovascular imaging as Journal Article, Validation Study, Comparative Study, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Time-of-Flight PET/CT Imaging of Ga-68-Dotatate: Normal Pattern, SUV Quantification, and Differences from Non-Time-of-Flight Imaging.↗

    PubMed lists PMID 38933071 in World journal of nuclear medicine as Journal Article, with publication-date metadata of 2024-05-07 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1.↗

    PubMed lists PMID 38563291 in Journal of medical imaging and radiation oncology as Journal Article, with publication-date metadata of 2024-04-02 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT03953131↗

    PeptideScanner retained ClinicalTrials.gov record NCT03953131 at 2026-11-16T17:36:42.191Z. Its registry update date was 2023-09-01, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.↗

  12. Literature metadata

    Doing Great With DOTATATE: Update on GA-68 DOTATATE Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Evaluation of Sinonasal Tumors.↗

    PubMed lists PMID 34096898 in Topics in magnetic resonance imaging : TMRI as Journal Article, Review, with publication-date metadata of 2021-06-01 (day precision). PeptideScanner associated the retained record with the identity slug gallium-ga-68-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection) · SPL version 23 · published 2026-07-07 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: NETSPOT (gallium dotatate Ga-68), NDA 208547 · original approval June 1, 2016 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026